CN102869666B - 用于疾病治疗的组胺受体的杂环抑制剂 - Google Patents

用于疾病治疗的组胺受体的杂环抑制剂 Download PDF

Info

Publication number
CN102869666B
CN102869666B CN201180019492.3A CN201180019492A CN102869666B CN 102869666 B CN102869666 B CN 102869666B CN 201180019492 A CN201180019492 A CN 201180019492A CN 102869666 B CN102869666 B CN 102869666B
Authority
CN
China
Prior art keywords
compound
purposes
mmol
pyrazine
triazolo
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
CN201180019492.3A
Other languages
English (en)
Chinese (zh)
Other versions
CN102869666A (zh
Inventor
艾伦·布查德特
罗伯特·戴维斯
斯图华特·A·诺布尔
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Kalypsys Inc
Original Assignee
Kalypsys Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Kalypsys Inc filed Critical Kalypsys Inc
Publication of CN102869666A publication Critical patent/CN102869666A/zh
Application granted granted Critical
Publication of CN102869666B publication Critical patent/CN102869666B/zh
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/4985—Pyrazines or piperazines ortho- or peri-condensed with heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/02—Nasal agents, e.g. decongestants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/04—Antipruritics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/16—Otologicals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D498/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D498/04—Ortho-condensed systems

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Pulmonology (AREA)
  • Rheumatology (AREA)
  • Dermatology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Ophthalmology & Optometry (AREA)
  • Pain & Pain Management (AREA)
  • Otolaryngology (AREA)
  • Transplantation (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Plural Heterocyclic Compounds (AREA)
CN201180019492.3A 2010-03-10 2011-03-10 用于疾病治疗的组胺受体的杂环抑制剂 Expired - Fee Related CN102869666B (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US31261510P 2010-03-10 2010-03-10
US61/312,615 2010-03-10
PCT/US2011/027817 WO2011112766A2 (en) 2010-03-10 2011-03-10 Heterocyclic inhibitors of histamine receptors for the treatment of disease

Publications (2)

Publication Number Publication Date
CN102869666A CN102869666A (zh) 2013-01-09
CN102869666B true CN102869666B (zh) 2015-09-09

Family

ID=44564108

Family Applications (1)

Application Number Title Priority Date Filing Date
CN201180019492.3A Expired - Fee Related CN102869666B (zh) 2010-03-10 2011-03-10 用于疾病治疗的组胺受体的杂环抑制剂

Country Status (18)

Country Link
US (1) US8569300B2 (enExample)
EP (1) EP2545058B1 (enExample)
JP (1) JP5888654B2 (enExample)
KR (1) KR20130016253A (enExample)
CN (1) CN102869666B (enExample)
AR (1) AR080496A1 (enExample)
AU (1) AU2011224316B2 (enExample)
BR (1) BR112012022211A2 (enExample)
CA (1) CA2791417A1 (enExample)
ES (1) ES2607125T3 (enExample)
IL (1) IL221829A (enExample)
MX (1) MX2012010404A (enExample)
NZ (1) NZ602041A (enExample)
PH (1) PH12012501783A1 (enExample)
RU (1) RU2012137180A (enExample)
TW (1) TW201200518A (enExample)
UY (1) UY33271A (enExample)
WO (1) WO2011112766A2 (enExample)

Families Citing this family (40)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8859550B2 (en) * 2011-09-12 2014-10-14 Kalypsys, Inc. Heterocyclic inhibitors of histamine receptors for the treatment of disease
US9266891B2 (en) 2012-11-16 2016-02-23 Boehringer Ingelheim International Gmbh Substituted [1,2,4]triazolo[4,3-A]pyrazines that are BRD4 inhibitors
AP2015008843A0 (en) 2013-05-02 2015-11-30 Pfizer Imidazo-triazine derivatives as pde10 inhibitors
DK3290407T3 (da) 2013-10-18 2020-03-23 Celgene Quanticel Res Inc Bromodomæneinhibitorer
US9527835B2 (en) 2014-02-13 2016-12-27 Incyte Corporation Cyclopropylamines as LSD1 inhibitors
NZ723203A (en) 2014-02-13 2020-08-28 Incyte Corp Cyclopropylamines as lsd1 inhibitors
EP3392244A1 (en) 2014-02-13 2018-10-24 Incyte Corporation Cyclopropylamines as lsd1 inhibitors
KR102421235B1 (ko) 2014-02-13 2022-07-15 인사이트 코포레이션 Lsd1 저해제로서 사이클로프로필아민
US9695180B2 (en) 2014-07-10 2017-07-04 Incyte Corporation Substituted imidazo[1,2-a]pyrazines as LSD1 inhibitors
WO2016007722A1 (en) 2014-07-10 2016-01-14 Incyte Corporation Triazolopyridines and triazolopyrazines as lsd1 inhibitors
WO2016007731A1 (en) 2014-07-10 2016-01-14 Incyte Corporation Imidazopyridines and imidazopyrazines as lsd1 inhibitors
US9758523B2 (en) 2014-07-10 2017-09-12 Incyte Corporation Triazolopyridines and triazolopyrazines as LSD1 inhibitors
TW201625635A (zh) 2014-11-21 2016-07-16 默沙東藥廠 作為可溶性鳥苷酸環化酶活化劑之三唑并吡基衍生物
CN107108637B (zh) 2014-12-23 2019-10-29 诺华股份有限公司 三唑并嘧啶化合物及其用途
UA122688C2 (uk) 2015-04-03 2020-12-28 Інсайт Корпорейшн Гетероциклічні сполуки як інгібітори lsd1
JP7427363B2 (ja) 2015-08-12 2024-02-05 インサイト・ホールディングス・コーポレイション Ｌｓｄ１阻害剤の塩
US10166221B2 (en) 2016-04-22 2019-01-01 Incyte Corporation Formulations of an LSD1 inhibitor
US10676479B2 (en) 2016-06-20 2020-06-09 Novartis Ag Imidazolepyridine compounds and uses thereof
IL263429B (en) 2016-06-20 2022-08-01 Novartis Ag Crystalline forms of triazolopyrimidine compound
WO2017221092A1 (en) 2016-06-20 2017-12-28 Novartis Ag Triazolopyridine compounds and uses thereof
UY37556A (es) 2017-01-10 2018-07-31 Bayer Ag Derivados heterocíclicos como pesticidas
AU2018208422B2 (en) 2017-01-10 2021-11-11 Bayer Aktiengesellschaft Heterocyclene derivatives as pest control agents
BR112019015075A2 (pt) 2017-01-23 2020-03-10 Revolution Medicines, Inc. Compostos bicíclicos como inibidores de shp2 alostéricos
EP3652169A1 (en) 2017-08-01 2020-05-20 Theravance Biopharma R&D IP, LLC Pyrazolo and triazolo bicyclic compounds as jak kinase inhibitors
SG11202002941WA (en) 2017-10-12 2020-04-29 Revolution Medicines Inc Pyridine, pyrazine, and triazine compounds as allosteric shp2 inhibitors
CA3084058A1 (en) * 2017-12-15 2019-06-20 Revolution Medicines, Inc. Polycyclic compounds as allosteric shp2 inhibitors
CN110655520A (zh) * 2018-06-29 2020-01-07 上海青煜医药科技有限公司 嘧啶并环化合物及其制备方法和应用
CN115448923B (zh) * 2018-02-13 2024-03-22 上海青煜医药科技有限公司 嘧啶并环化合物及其制备方法和应用
MA51845A (fr) * 2018-02-13 2020-12-23 Shanghai Blueray Biopharma Co Ltd Composé cyclique fusionné à une pyrimidine, son procédé de préparation et son application
BR122023024273A2 (pt) 2018-02-27 2024-02-20 Incyte Corporation Compostos imidazopirimidinas e triazolopirimidinas, seus usos, método para inibir uma atividade de um receptor de adenosina e composição farmacêutica dos mesmos
EP3810610A1 (en) 2018-05-18 2021-04-28 Incyte Corporation Fused pyrimidine derivatives as a2a / a2b inhibitors
AU2019297361B2 (en) 2018-07-05 2024-06-27 Incyte Corporation Fused pyrazine derivatives as A2A / A2B inhibitors
WO2020047198A1 (en) 2018-08-31 2020-03-05 Incyte Corporation Salts of an lsd1 inhibitor and processes for preparing the same
ES2973117T3 (es) 2018-09-25 2024-06-18 Incyte Corp Compuestos de pirazolo[4,3-d]pirimidina como moduladores de ALK2 y/o FGFR
JP2022506887A (ja) * 2018-11-07 2022-01-17 シャンハイ リンジーン バイオファーマ カンパニー リミテッド 窒素含有縮合複素環系ｓｈｐ２阻害剤化合物、製造方法及び使用
EP3889153A4 (en) * 2018-11-30 2022-09-07 Tuojie Biotech (Shanghai) Co., Ltd. PYRIMIDINE AND FIVE-MEMBERED HETEROCYCLIC NITROGEN DERIVATIVE, METHOD OF MANUFACTURE THEREOF AND MEDICAL USES THEREOF
JP2022518741A (ja) 2019-01-23 2022-03-16 セラヴァンス バイオファーマ アール＆ディー アイピー， エルエルシー ＪＡＫキナーゼ阻害剤としてのイミダゾ［１，５－ａ］ピリジン、１，２，４－トリアゾロ［４，３－ａ］ピリジンおよびイミダゾ［１，５－ａ］ピラジン
TWI829857B (zh) 2019-01-29 2024-01-21 美商英塞特公司 作為a2a / a2b抑制劑之吡唑并吡啶及三唑并吡啶
WO2021032004A1 (zh) * 2019-08-22 2021-02-25 上海青煜医药科技有限公司 氮杂芳基化合物及其应用
US12065444B2 (en) 2021-11-19 2024-08-20 Crossignal Therapeutics, Inc. Substituted tetrazolo[1,5-a]pyrazines and tetrazolo[1,5-c]pyrimidines as adenosine receptor antagonists

Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2008003702A2 (en) * 2006-07-03 2008-01-10 Vereniging Voor Christelijk Hoger Onderwijs, Wetenschappelijk Onderzoek En Patientenzorg Fused bicyclic compounds interacting with the histamine h4 receptor
US20080139572A1 (en) * 2006-04-25 2008-06-12 Bristol-Myers Squibb Company Diketo-piperazine and piperidine derivatives as antiviral agents
WO2009089547A1 (en) * 2008-01-11 2009-07-16 Fibrogen, Inc. Isothiazole-pyridine derivatives as modulators of hif (hypoxia inducible factor) activity
WO2009098320A2 (en) * 2008-02-08 2009-08-13 Basilea Pharmaceutica Ag Macrolides and uses of macrolides
WO2010030757A2 (en) * 2008-09-10 2010-03-18 Kalypsys Inc. Aminopyrimidine inhibitors of histamine receptors for the treatment of disease
WO2011019780A1 (en) * 2009-08-11 2011-02-17 Bristol-Myers Squibb Company Azaindazoles as btk kinase modulators and use thereof

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3929812A (en) * 1974-05-20 1975-12-30 Squibb & Sons Inc Derivatives of 1H-triazolo {8 4,5-c{9 pyridine-7-carboxylic acids and esters
DE4337611A1 (de) * 1993-11-04 1995-05-11 Boehringer Ingelheim Kg Neue Benzoylguanidine, ihre Herstellung und ihre Verwendung in Arzneimitteln
US20040110826A1 (en) * 2001-09-28 2004-06-10 Noriaki Uesaka Receptor Antagonists
US6921762B2 (en) * 2001-11-16 2005-07-26 Amgen Inc. Substituted indolizine-like compounds and methods of use
WO2004000841A1 (ja) * 2002-06-25 2003-12-31 Kyowa Hakko Kogyo Co., Ltd. 二環性複素環化合物
CA2497827A1 (en) 2002-09-06 2004-03-18 Janssen Pharmaceutica, N.V. (1h-benzoimidazol-2-yl)-(piperazinyl)-methanone derivatives and related compounds as histamine h4-receptor antagonists for the treatment of inflammatory and allergic disorders
JP2008501758A (ja) * 2004-06-09 2008-01-24 グラクソ　グループ　リミテッド ピロロピリジン誘導体
US20090182140A1 (en) * 2005-12-02 2009-07-16 Mitsubishi Tanabe Pharma Corporation Alicyclic Heterocyclic Compound
DE602007006010D1 (de) * 2006-05-31 2010-06-02 Galapagos Nv Triazolopyrazinverbindungen zur behandlung von degenerations- und entzündungskrankheiten
US20100035863A1 (en) 2006-09-12 2010-02-11 Ucb Pharma, S.A. 2 Amino-Pyrimidine Derivatives As H4 Receptor Antagonists, Processes For Preparing Them And Their Use In Pharmaceutical Compositions
AU2009291719A1 (en) * 2008-09-10 2010-03-18 Alcon Research, Ltd Heterocyclic inhibitors of histamine receptors for the treatment of disease
NZ596185A (en) * 2009-04-16 2013-01-25 Ct Nac Investigaciones Oncologicas Cnio Imidazopyrazines for use as kinase inhibitors
ME02432B (me) 2009-12-17 2016-09-20 Merial Inc Antiparazitska jedinjenja dihidroazola i kompozicije koje ih sadrže
WO2011089400A1 (en) 2010-01-22 2011-07-28 Centro Nacional De Investigaciones Oncológicas (Cnio) Inhibitors of pi3 kinase
US20110190269A1 (en) * 2010-02-01 2011-08-04 Karlheinz Baumann Gamma secretase modulators
US20110237599A1 (en) * 2010-03-10 2011-09-29 Kalypsys, Inc. Heterocyclic inhibitors of histamine receptors for the treatment of disease

Patent Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20080139572A1 (en) * 2006-04-25 2008-06-12 Bristol-Myers Squibb Company Diketo-piperazine and piperidine derivatives as antiviral agents
WO2008003702A2 (en) * 2006-07-03 2008-01-10 Vereniging Voor Christelijk Hoger Onderwijs, Wetenschappelijk Onderzoek En Patientenzorg Fused bicyclic compounds interacting with the histamine h4 receptor
WO2009089547A1 (en) * 2008-01-11 2009-07-16 Fibrogen, Inc. Isothiazole-pyridine derivatives as modulators of hif (hypoxia inducible factor) activity
WO2009098320A2 (en) * 2008-02-08 2009-08-13 Basilea Pharmaceutica Ag Macrolides and uses of macrolides
WO2010030757A2 (en) * 2008-09-10 2010-03-18 Kalypsys Inc. Aminopyrimidine inhibitors of histamine receptors for the treatment of disease
WO2011019780A1 (en) * 2009-08-11 2011-02-17 Bristol-Myers Squibb Company Azaindazoles as btk kinase modulators and use thereof

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
Ring Opening of [l,2,3]Triazolo[l,5-a]Pyrazinium Salts: Synthesis and Some Transformations of a Novel Type of 2-Aza-l,3-butadienes;Mariann Beres，等;《Tetrahedron》;19970707;第53卷(第27期);第9393-9400页 *
Shuntaro Mataka,等."Reduction of 4,7-Diphenyl-1,2,5-thia(oxa)diazolo[3,4-c]pyridines Affording 2,5-Diphenyl-3,4-diaminopyridines and Ring Closure of the Diamines to Fluorescent Azaheterocycles.《Journal of Heterocyclic Chemistry》.1982,第19卷(第6期),第1481-1488页. *
Sythesis of 2,5-bis-Arylpyridines by [4+2]Cycloaddition of 1,4-bis Aryl-2-aza-1,3-butadienes with Electron-Poor Dienophiles;Jean-Laurent Paparin，等;《Journal of Heterocyclic Chemistry》;20000301;第37卷(第2期);第411-418页 *

Also Published As

Publication number Publication date
MX2012010404A (es) 2013-05-20
AU2011224316B2 (en) 2016-09-15
AU2011224316A1 (en) 2012-09-13
TW201200518A (en) 2012-01-01
WO2011112766A2 (en) 2011-09-15
JP2013522222A (ja) 2013-06-13
RU2012137180A (ru) 2014-04-20
IL221829A (en) 2014-11-30
PH12012501783A1 (en) 2015-06-26
CA2791417A1 (en) 2011-09-15
ES2607125T3 (es) 2017-03-29
US8569300B2 (en) 2013-10-29
US20110237565A1 (en) 2011-09-29
JP5888654B2 (ja) 2016-03-22
WO2011112766A3 (en) 2012-01-19
AR080496A1 (es) 2012-04-11
KR20130016253A (ko) 2013-02-14
BR112012022211A2 (pt) 2017-07-18
EP2545058A4 (en) 2013-07-24
UY33271A (es) 2011-10-31
NZ602041A (en) 2014-08-29
EP2545058B1 (en) 2016-08-24
EP2545058A2 (en) 2013-01-16
CN102869666A (zh) 2013-01-09

Similar Documents

Publication Publication Date Title
JP5888654B2 (ja) 疾患の治療のためのヒスタミン受容体の複素環阻害薬
CN102186479A (zh) 用于治疗疾病的组胺受体的氨基嘧啶抑制剂
CN102388044A (zh) 用于治疗疾病的组胺受体的杂环抑制剂
KR102815607B1 (ko) 전사 활성화 단백질의 이미다조피페라진 억제제
US20110257137A1 (en) Heterocyclic inhibitors of histamine receptors for the treatment of disease
US20110237599A1 (en) Heterocyclic inhibitors of histamine receptors for the treatment of disease
US8080566B1 (en) Carbazole inhibitors of histamine receptors for the treatment of disease
WO2010088518A2 (en) Heterocyclic modulators of gpr119 for treatment of disease
CN107635404A (zh) 用于治疗疾病的mct4抑制剂
EP4221709B1 (en) Imidazopiperazine inhibitors of transcription activating proteins
WO2013039785A2 (en) Heterocyclic inhibitors of histamine receptors for the treatment of disease
US20260132138A1 (en) Imidazopiperazine inhibitors of transcription activating proteins
HK1181038B (en) Tetrazolo[1,5-a]pyrazine compounds as inhibitors of histamine receptors

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
C14 Grant of patent or utility model
GR01 Patent grant
CF01 Termination of patent right due to non-payment of annual fee

Granted publication date: 20150909

Termination date: 20190310

CF01 Termination of patent right due to non-payment of annual fee